SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?


To: Hank who wrote (3922)5/5/1998 11:06:00 AM
From: Dauntless  Read Replies (1) | Respond to of 7041
 
Hank - Everyone is entitled to their opinion

SGP/Zona will not be standing still either. They are already working on the female version and a "combined" compound.



To: Hank who wrote (3922)5/5/1998 11:24:00 AM
From: Jumper  Respond to of 7041
 
Hank, you should also keep in mind the Buy Rec out from Don Imus.

Every day Mr. Imus & his sidekick read third tier newspaper articles on the air, they may have stumbled on a real gem here.



To: Hank who wrote (3922)5/5/1998 9:45:00 PM
From: Fernando Saldanha  Respond to of 7041
 
Hank, I tend to play stocks like ZONA on the short side, and have followed Roger Babb's threads for a long time. Independently of the fundamentals behind Zonagen, which I am unable to evaluate, I think it is far too dangerous to short this stock at this point. Zonagen's market capitalization is "only" about $500 million. This is peanuts for today's inflated standards. Zonagen could easily be valued at over $1 billion, if people start believing that Vasomax will be a big drug. The hype on Viagra can only be compared to the internet frenzy (KTEL is up 14 times in one month, Market Guide was up 10 times in one morning). You may or not be right about the drug and about Joe Podolsky's ethics, but the stock can take a walk on the stratosphere before we find out the truth. Is it really worthwhile shorting this stock, I mean in terms of risk-reward ratio?

Best regards.